Santaris Inks LNA Rx Deal with Shire, Leveraging Technology in Areas Outside of Core Focus | GenomeWeb

By Doug Macron

Santaris Pharma announced this week that it has signed a deal to use its locked nucleic acid technology to develop drug candidates against rare genetic disorders for British biopharmaceutical firm Shire.

The deal, which calls for Shire to handle the majority of the drugs’ development, provides Santaris with a way to realize additional value from its technology in areas outside of its core expertise as it advances its own therapeutic programs, Santaris CSO Henrik Orum told RNAi News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.